Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. - ROEverified

LCTX

Price:

$1.14

Market Cap:

$284.20M

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensor...[Read more]

Industry

Biotechnology

IPO Date

1992-03-05

Stock Exchange

AMEX

Ticker

LCTX

The ROE as of August 2026 (TTM) for Lineage Cell Therapeutics, Inc. (LCTX) is -152.10%

According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -152.10%. This represents a change of 196.63% compared to the average of -51.28% of the last 4 quarters.

Lineage Cell Therapeutics, Inc. (LCTX) Historical ROE (quarterly & annually)

How has LCTX ROE performed in the past?

The mean historical ROE of Lineage Cell Therapeutics, Inc. over the last ten years is -34.74%. The current -152.10% ROE has changed 337.88% with respect to the historical average. Over the past ten years (40 quarters), LCTX's ROE was at its highest in in the September 2018 quarter at 38.99%. The ROE was at its lowest in in the September 2025 quarter at -135.12%.

Quarterly (TTM)
Annual

Average

-34.74%

Median

-28.81%

Minimum

-142.61%

Maximum

28.47%

Lineage Cell Therapeutics, Inc. (LCTX) ROE by Quarter and Year

Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 500.69%

Maximum Annual ROE = 28.47%

Minimum Annual Increase = -143.14%

Minimum Annual ROE = -142.61%

Quarterly (TTM)
Annual
YearROEChange
2025-142.61%500.69%
2024-23.74%-29.92%
2023-33.88%-5.43%
2022-35.82%-23.20%
2021-46.65%117.32%
2020-21.46%107.08%
2019-10.37%-78.85%
2018-49.01%299.02%
2017-12.28%-143.14%
201628.47%-116.29%

Lineage Cell Therapeutics, Inc. (LCTX) Average ROE

How has LCTX ROE performed in the past?

The current ROE of Lineage Cell Therapeutics, Inc. (LCTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-66.74%

5-year avg

-56.54%

10-year avg

-34.74%

Lineage Cell Therapeutics, Inc. (LCTX) ROE vs. Peers

How is LCTX’s ROE compared to its peers?

Lineage Cell Therapeutics, Inc.’s ROE is greater than Neurogene Inc. (-37.88%), greater than Ocugen, Inc. (-127987.50%), greater than Benitec Biopharma Inc. (-34.82%), less than ADC Therapeutics S.A. (65.27%), greater than Autolus Therapeutics plc (-128.53%), greater than Fulcrum Therapeutics, Inc. (-28.54%), less than PureTech Health plc (0%), less than Galectin Therapeutics Inc. (21.05%), greater than Omeros Corporation (-54.39%), greater than RAPT Therapeutics, Inc. (-31.83%),

Build a custom stock screener for Lineage Cell Therapeutics, Inc. (LCTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lineage Cell Therapeutics, Inc. (LCTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Lineage Cell Therapeutics, Inc.'s ROE?

How is the ROE calculated for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the highest ROE for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the 3-year average ROE for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the 5-year average ROE for Lineage Cell Therapeutics, Inc. (LCTX)?

How does the current ROE for Lineage Cell Therapeutics, Inc. (LCTX) compare to its historical average?